Business UpdateJul 7, 2026, 07:26 AM
Dyadic C1 Platform Validated in Global Health Collaborations
AI Summary
Dyadic International highlighted continued progress across multiple global health collaborations, validating its proprietary C1 protein production platform. These collaborations, including those with the Gates Foundation, CEPI/FBS, and Scripps Research, demonstrate C1's potential for rapid, high-yield, and cost-efficient production of biologics. The company also received the final payment of a $3.1 million Gates Foundation grant, fully funding ongoing research.
Key Highlights
- Received final $738,743 payment of Gates Foundation grant in June 2026, fully funding research.
- CEPI/FBS program demonstrated plasmid-to-purified-protein production in approximately 15 days.
- Initial purified antigen samples for Scripps Research collaboration expected by end of July 2026.
- Global biologics market exceeds $690 billion, projected to surpass $1.3 trillion by 2033.
- Monoclonal antibodies account for over 65% of biologic sales.
- C1 platform's addressable market opportunity is estimated at over $25 billion.
Price Impact
More from DYAI